Canndoc is developing pharma-grade cannabis products. Over the years, Canndoc has provided more than 500,000 doses to 15,000 patients, demonstrating expertise across the value chain from research, cultivation, and processing to product development and good manufacturing practice (GMP) clinical trial pipeline initiation. Driven by the mission of meeting patients' needs and improving their quality of life, Canndoc's GMP-standard products are prescribed for a range of indications including neuropathic pain, pain from cancer, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's disease, and epileptic seizures. Canndoc is a fully owned subsidiary of Israeli Medical Cannabis, Intercure. Its products and genetics cover European, Canadian, and Israeli regulatory requirements.